Vulvar cancer is the fourth most common gynaecological malignancy in developed countries with an incidence of approximately 2 cases per 100 000 women each year ([@bib27]; [@bib22]; [@bib10]). This cancer is mostly seen in post-menopausal women, and the average age at diagnosis is 70 years. Nearly 90% of all vulvar carcinomas are vulvar squamous cell carcinoma (VSCC) ([@bib13]). Squamous cell carcinomas of the vulva can be divided into two aetiological types ([@bib32]; [@bib3]). The first type is seen mainly in younger patients and is associated with human papillomavirus (HPV) infection ([@bib31]). The second type is seen mostly in elderly patients and seems to develop independent of HPV infection. This type of carcinoma is associated with lichen sclerosis and mutations of the *TP53* gene ([@bib32]; [@bib31]).

Vulvar carcinoma generally has a good prognosis when detected and treated at an early stage, but the most common treatment modalities, that is, surgical removal and/or radiotherapy, can be mutilating and have high morbidity rates ([@bib2]; [@bib12]; [@bib9]). A small proportion of patients suffer from early recurrence, rapid progression of tumour growth and death ([@bib33]). Identifying risk factors for poor survival is important to further reduce the mortality and morbidity of vulvar cancer patients, but few studies have found new factors of clinical importance ([@bib16]). To date, lymph node involvement is the only accurate prognostic factor for survival and recurrence ([@bib18]).

A specific histological type of squamous cell carcinoma, termed spindle cell carcinoma, is seen occasionally. Spindle cell carcinoma is also referred to as pseudosarcoma or carcinosarcoma. Spindle cells are thin, slender, elongated cancer cells that infiltrate stromal tissue and that occur either as single cells or as cords of cells rather than as groups or islands ([Figure 1](#fig1){ref-type="fig"}). Spindle cell carcinoma is seen in many different types of cancer and is associated with a worse prognosis in cancers of the oral cavity, oesophagus and lung ([@bib23]; [@bib1]; [@bib17]; [@bib20]; [@bib29]). Spindle-shaped epithelial cancer cells have lost their typical epithelial characteristics and seem to gain the ability to infiltrate the underlying stroma and metastasize ([@bib15]).

Spindle cell carcinomas consisting of spindle cells alone have been reported only incidentally in vulvar carcinoma, and it is thought to be an aggressive tumour type that occurs in 1--5% of all VSCC patients ([@bib26]; [@bib23]; [@bib5]; [@bib6]; [@bib24]; [@bib4]; [@bib21]; [@bib28]). Some VSCCs show a specific pattern of invasion in which there is infiltration of the stroma by single cells or cords of tumour cells adjacent to the 'conventional\' squamous cell carcinoma cells. This pattern is also called 'spray pattern invasion\'. This spray pattern invasion is seen more often than the rare vulvar spindle cell carcinoma and has been described before ([@bib8]; [@bib14]; [@bib11]). A subpopulation of these vulvar carcinomas with a spray pattern of invasion clearly shows areas of infiltrating cells that resemble spindle cell carcinoma. We suggest that these tumours be termed 'vulvar squamous cell carcinomas with spindle cell morphology\' and describe the criteria used to characterise these tumours in the Materials and Methods section. The characteristics of tumours with this pattern of invasion and their association with survival have, to our knowledge, not been studied in a large cohort of patients. We hypothesize that tumours with spindle cell morphology, that is, tumours consisting of both 'conventional\' squamous cell carcinoma cells and spindle cells, may share some of the aetiology and clinical behaviour with the aggressive spindle cell carcinomas. We considered whether spindle cell morphology is a possible risk factor and studied its prevalence and possible relation with prognosis.

Materials and methods
=====================

Patients
--------

All patients who were primarily surgically treated for primary VSCC between 2000 and 2009 at the Leiden University Medical Center, a referral centre for gynaecological cancers in The Netherlands, were considered for inclusion in this study.

Clinical and follow-up data were retrieved from patient medical records and from the cancer registration database. Patients were excluded if they had received systemic immunosuppressive therapy, chemotherapy or radiotherapy in the pelvic area before surgery. Tumour staging was performed according to the FIGO system using histologically confirmed TNM data. We used the 1995 staging instead of the revised 2009 staging because of the retrospective design of the study ([@bib7]; [@bib19]). The patients were followed up until December 2012. Patient samples were handled according to the medical ethical guidelines described in the Code of Conduct for Proper Secondary Use of Human Tissue of the Dutch Federation of Biomedical Scientific Societies.

Microscopy and immunohistochemistry
-----------------------------------

All formalin-fixed, paraffin-embedded tissue blocks from the selected primary VSCC patients that were stored in the Leiden University Medical Center archives were examined microscopically for the presence of spindle-shaped tumour cells on haematoxylin and eosin-stained slides. Tumours from which only biopsies were taken were excluded from the study.

One series of consecutive 4-*μ*m paraffin-embedded tissue sections was taken from all tumour-containing tissue blocks and stained as described previously ([@bib25]) using primary antibodies for pankeratin AE1AE3 (mAB 3412, 1 : 2000, Millipore, Billerica, MA, USA), keratin 10 (DE-k10, 1 : 50, DAKO, Glostrup, Denmark) and keratin 14 (LL002, 1 : 2000, Abcam, Cambridge, UK). All slides were digitalised using a Mirax slide scanner and analysed using Panoramic Viewer (version 1.15.50, 3DHistec, Budapest, Hungary).

As there is no established definition of spindle cell morphology, we categorised the samples as follows. Tumour cells were categorised as spindle cells if they had an elongated shape, infiltrated the underlying stromal tissue as single cells or as cords of cells instead of as islands of cells and were keratin 14-positive and keratin 10-negative as markers of dedifferentiation ([Figure 2](#fig2){ref-type="fig"}). When at least 10 spindle cells were seen per high power field using a 40 × 0.65 objective, independent of the proportion of spindle cells in relation to the solid component of the cancer, the tumour was categorised as having spindle cell morphology. Spindle-shaped cells in close proximity (\<0.5 mm) to the solid component of the tumour were not marked as spindle cell carcinoma cells but were considered to be a part of the spray pattern invasive border of the solid tumour.

HPV analysis
------------

DNA extracted from formalin-fixed, paraffin-embedded tumour tissue was used for HPV-type analysis. To prevent and check for contamination, sections of a paraffin block without tissue, which were cut before each tumour sample, served as negative controls. All such controls were negative in the PCR analysis. The INNO-LiPA HPV Genotyping *Extra* Amp kit (Innogenetics, Gent, Belgium) for *in vitro* diagnostic use, which is a highly sensitive hybridisation assay, was used for HPV typing as described previously ([@bib34]). This assay is able to detect oncogenic and common HPV types ([@bib34]).

Statistical analysis
--------------------

Statistical analyses were conducted using the IBM SPSS Statistics software package (version 20, IBM-SPSS Statistics, Armonk, NY, USA). The independent *t*-test was used to compare baseline variables, and the Fisher\'s exact test was used to analyse categorical and normally distributed numerical data. The Shapiro--Wilk test was used to test for normality. The Mann--Whitney *U* test was used for data with a skewed distribution. Kaplan--Meier curves, the log rank test and Cox\'s Proportional Hazard regression analysis were performed to analyse the differences in survival between the spindle and non-spindle groups. A *P*-value⩽0.05 was considered significant, corresponding to 95% confidence intervals. All tests were two-tailed. Results for normally distributed numerical data are presented as mean with standard deviation (s.d.), and results for skewed numerical data are presented as median with interquartile range (IQR).

Disease-free survival was defined as survival from the date of surgery until the first recurrence or death or until the end of study follow-up. The overall survival of the patients was measured from the date of surgery until death from any cause or until the end of study follow-up. Disease-specific survival was measured from the date of surgery until death from vulvar cancer or until the end of study follow-up. Recurrent disease in the vulvar area was characterised as 'local recurrence\', whereas recurrences in the inguinal region were characterised as 'regional recurrence\'. Recurrent disease on the contralateral side of the vulva was considered to be a second primary tumour.

Results
=======

Between January 2000 and December 2009, 129 patients were treated surgically for primary VSCC at the Leiden University Medical Center. Nine patients were excluded, because they had a history of chemotherapy, pelvic radiotherapy or immunosuppressive therapy for vulvar cancer or for another disease before the current diagnosis. Eleven patients were excluded, because their tumours were biopsied, but no further surgical treatment was given. Tumour tissue from one patient was of poor quality and was not analysed further. Thus, a total of 108 patients with primary VSCC met all of our inclusion criteria. [Table 1](#tbl1){ref-type="table"} lists the characteristics of these patients.

The median follow-up time was 39 months (IQR 16.3--70.5), and the mean age at diagnosis with vulvar carcinoma was 69.9 years (s.d. 14.1). Symptoms first occurred at a median of 5.0 months (IQR 2.0--18.0) before diagnosis. Microscopic evaluation showed a mean tumour size of 32.1 mm (s.d. 22.2) and a median infiltration depth of 6.0 mm (IQR 4.0--11.0). Lymph node metastases were found in 41 of the 108 patients (38.0%). Thirty patients (27.8%) had a tumour that was FIGO stage 1, 36 patients (33.9%) stage 2, 30 (27.8%) stage 3 and 12 (11.1%) stage 4. Forty-three patients (39.8%) received adjuvant radiotherapy to the groin and/or vulva; 38 of these patients received adjuvant radiotherapy, because they were stage 3 or higher, and 5 of them received it because a tumour-free resection margin of \<8 mm was obtained. One patient received adjuvant radiotherapy and chemotherapy because of close tumour-free resection margins plus the presence of multiple inguinal lymph node metastases.

At the end point of the study period, 20% of the patients had developed local recurrent disease and 26% had died from the disease, giving a 5-year disease-free survival of 31% (s.d. 4.9) and a 5-year disease-specific survival of 73% (s.d. 4.5).

Comparison of the clinical outcomes for patients with spindle and non-spindle cell morphology
---------------------------------------------------------------------------------------------

Of the 108 tumours that were analysed, 22 tumours (20%) were identified as having spindle cell morphology and 86 (80%) as being non-spindle cell carcinomas. [Table 2](#tbl2){ref-type="table"} summarises the outcome measurements for patients with carcinomas with spindle cell and non-spindle cell morphology. The mean age did not differ between the two groups. Vulvar spindle cell carcinoma patients were diagnosed at a higher FIGO stage than non-spindle patients, though the duration of symptoms before diagnosis did not differ.

Forty-one of the 108 patients had lymph node metastases at the time of diagnosis, 15 of which were also positive for spindle cells. This gives a relative risk of lymph node metastasis in spindle cell morphology patients of 2.26 (95% CI 1.47--3.47) compared with patients without spindle cell morphology. Eighteen of 108 patients tested positive for HPV (type 16 (*n*=10), 18 (*n*=2) or 33 (*n*=5); one patient tested positive for both HPV types 16 and 33). None of these patients had carcinomas with spindle cell morphology.

Compared with spindle cell morphology patients, more non-spindle patients achieved complete remission (83.7% *vs* 50.0%, *P*=0.003). At the end point of the study period, 22.7% of the spindle cell morphology patients and 19.8% of the non-spindle cell patients had developed local recurrent disease, and 9.1% and 8.1% of patients, respectively, developed regional recurrences (*P*=1.000). In terms of disease-specific death, 50% of the spindle cell patients and 19.8% of the non-spindle cell patients died from the disease (*P*=0.002).

Overall survival differed significantly between patients with and without vulvar spindle cell morphology ([Figure 3A](#fig3){ref-type="fig"}), with a 5-year overall survival of 27.3% (s.d. 9.5) *vs* 58.2% (s.d. 5.6; *P*=0.00041), respectively. Disease-specific survival was significantly worse for spindle cell morphology patients than for non-spindle cell morphology patients, with a 5-year disease-specific survival of 45.2% (s.d. 11.4) *vs* 79.7% (s.d. 4.6; *P*=0.00057; [Figure 3B](#fig3){ref-type="fig"}). Five-year disease-free survival did not differ significantly between the two groups (25.0% *vs* 44.3%, *P*=0.149).

Univariate Cox regression analysis for disease-specific death resulted in a hazard ratio of 3.50 (95% CI 1.63--7.52, *P*=0.001) for spindle cell morphology patients compared with non-spindle cell patients. After correction for the possible confounders age and HPV infection, the hazard ratio became 2.71 (95% CI 1.26--5.81, *P*=0.011). When correcting for more tumour characteristics (tumour size, infiltration depth, positive resection margins), vulvar spindle cell morphology patients had a hazard ratio for disease-specific death of 2.51 (95% CI 1.12--5.64). Adding lymph node metastasis and regional or distant metastasis to the correction model gave a hazard ratio of 4.1 (95%CI 1.61--10.60) for patients with carcinomas with spindle cell morphology ([Table 3](#tbl3){ref-type="table"}).

Discussion
==========

This study is, to our knowledge, the first to investigate vulvar spindle cell morphology in a large group of patients with VSCC. Spindle cell morphology occurred frequently in our series and was found in 20% of the VSCCs examined. Carcinoma with spindle cell morphology has not been reported as a separate entity in vulvar cancer before this report. A spray pattern of invasion, which also includes spindle cell morphology, has been reported in a few papers ([@bib8]; [@bib14]; [@bib11]) and was found in 11 out of 26 VSCCs by [@bib11]. In the latter study, which was relatively small, a spray pattern of invasion was significantly associated with poor survival after correction for FIGO stage alone.

Our study of a large cohort of VSCC patients shows that patients with spindle cell morphology have a worse prognosis than patients with conventional squamous cell carcinoma of the vulva. The disease-specific and overall survival was almost half that of non-spindle squamous cell carcinoma patients. After correcting for multiple possible confounders, vulvar spindle cell morphology remains an independent prognostic factor. None of the patients with spindle cell morphology showed HPV infection, strongly suggesting that these tumours arise through the non-HPV pathway ([@bib32]; [@bib30]).

The vulvar spindle cell morphology patients reported having symptoms for a similar length of time before diagnosis than non-spindle cell patients, but VSCC patients presented with higher FIGO stages, possibly because of the aggressive character of spindle cells and the rapid progression of this type of tumour.

Although this series is the largest reported in the literature, the number of patients in this study is still too small to correct for all potential confounders. However, even after correcting for multiple tumour characteristics that are likely to be part of the causal path (tumour size, infiltration depth, positive resection margins, lymph node metastasis and distant metastasis), vulvar spindle cell morphology patients had a hazard ratio for disease-specific death of 4.14 (95% CI 1.61--10.60) relative to non-spindle cell patients, suggesting that the poor prognosis of these patients is associated with spindle cell morphology and is independent of other tumour characteristics. Caution has to be taken when interpreting multivariate analysis in small cohorts of patients. Given the distinct differences in survival, we suggest that this retrospective study be replicated at other large institutions to determine the added prognostic value of spindle cell morphology in a prognostic model.

Regarding the survival and overall incidence of spindle cells, selection bias could have been introduced by our inclusion of patients who were treated primarily by surgery. Patients who were treated by excision biopsy alone were not selected for this series, and such patients usually have smaller tumours and a better prognosis. On the other hand, patients with inoperable tumours, and likely a worse prognosis, were also not selected, so patient selection cannot fully explain the differences in survival. Notably, correcting for tumour size did not change the finding that spindle cell morphology patients have a significantly worse prognosis.

These results may have implications for the clinical management of VSCC. Spindle cells can be detected by a trained pathologist and, if necessary, be visualised using commonly available keratin stains. Given our finding that spindle cell morphology does not affect the risk of local recurrent disease, the current advice to perform a local radical tumour resection with 8-mm tumour-free margins after fixation seems appropriate ([@bib9]). However, the increased risk of lymph node metastasis and poorer prognosis could influence the choice to perform adjuvant chemotherapy or radiotherapy in vulvar spindle cell morphology patients.

Conclusion
==========

VSCC with spindle cell morphology appears to be an aggressive tumour type. In this series of patients, this cancer type had a worse prognosis than conventional VSCC as well as an increased risk of lymph node metastases at the time of diagnosis.

The authors declare no conflict of interest.

![**Representative images of (**A**) vulvar squamous cell carcinoma and (**B**) vulvar squamous cell carcinoma with spindle cell morphology ( × 20 magnification).**](bjc2013563f1){#fig1}

![**A representative image of a sample of vulvar squamous cell carcinoma with spindle cell morphology stained for (**A**) keratin 14 and (**B**) keratin 10.** Note that the spindle-shaped cells are positive for keratin 14 but negative for keratin 10, while the solid component of the tumour is positive for both keratins 14 and 10 (Bar=1000 *μ*m).](bjc2013563f2){#fig2}

![**(**A**) Overall survival and (**B**) disease-specific survival in the 108 vulvar squamous cell carcinoma patients in this study.** There were significant differences in both overall and disease-specific survival for patients who had carcinomas with *vs* without spindle cell morphology (relative risk of dying 1.7 *vs* 2.5; 95% CIs 1.3--2.3 and 1.4--4.6; *P*=0.0043 and *P*=0.0041, respectively).](bjc2013563f3){#fig3}

###### Characteristics of the vulvar squamous cell carcinoma patients in this study

  **Characteristic**                                              **Value**
  ---------------------------------------------------------- -------------------
  Follow-up (months)[a](#t1-fn2){ref-type="fn"}               39.0 (16.3--70.5)
  Age at diagnosis (years)[b](#t1-fn3){ref-type="fn"}            69.9 (14.1)
  Duration of symptoms (months)[a](#t1-fn2){ref-type="fn"}     5.0 (2.0--18.0)
  FIGO stage *n* (%)                                                   
  Stage 1                                                         30 (27.8)
  Stage 2                                                         36 (33.3)
  Stage 3                                                         30 (27.8)
  Stage 4                                                         12 (11.1)
  Treatment *n* (%)                                                    
  Radical vulvectomy                                              69 (63.9)
  Radical local excision                                          39 (36.1)
  Adjuvant radiotherapy                                           43 (39.8)
  Adjuvant chemotherapy                                            1 (0.9)
  HPV positive *n* (%)                                            18 (16.7)
  Lymph node metastases *n* (%)                                   41 (38.0)
  Unilateral                                                      29 (26.9)
  Bilateral                                                       12 (11.1)
  Extracapsular growth                                            17 (15.7)
  Tumour size (mm)[b](#t1-fn3){ref-type="fn"}                    32.1 (22.2)
  Infiltration depth (mm)[a](#t1-fn2){ref-type="fn"}           6.0 (4.0--11.0)
  Vasoinvasion *n* (%)                                            15 (13.9)
  Lymphangioinvasion                                               3 (2.8)
  Perineural growth                                                4 (3.7)
  Positive resection margins                                      21 (19.4)
  Disease status *n* (%)                                               
  Complete remission                                              83 (76.9)
  Local recurrence                                                22 (20.4)
  Second primary tumour                                           10 (9.3)
  Regional recurrence                                              9 (8.3)
  Regional metastases                                              8 (7.4)
  Distant metastases                                              24 (22.2)
  Died                                                            59 (54.6)
  Disease-specific death                                          28 (25.9)
  5-year overall survival % (s.d.)                               51.9 (5.0)
  5-year disease-specific survival % (s.d.)                      72.9 (4.5)
  5-year disease-free survival % (s.d.)                          30.7 (4.9)

Abbreviations: FIGO=International Federation of Gynecology and Obstetrics; HPV=human papillomavirus.

Median (interquartile range).

Mean (s.d.).

###### Comparison of the clinical outcomes for patients with spindle and non-spindle cell morphology

  **Outcome**                                                 **Spindle** ***n*****=22 (20.4%)**   **Non-spindle** ***n*****=86 (79.6%)**             ***P*-value**
  ---------------------------------------------------------- ------------------------------------ ---------------------------------------- ------------------------------------
  Follow-up (months)[a](#t2-fn2){ref-type="fn"}                        18.0 (8.8--46.0)                      48.0 (123.0--77.5)              0.026[b](#t2-fn3){ref-type="fn"}
  Age at diagnosis (years)[c](#t2-fn4){ref-type="fn"}                    71.0 (13.2)                            69.7 (14.4)                               0.617
  Duration of symptoms (months)[a](#t2-fn2){ref-type="fn"}             4.0 (2.8--12.5)                        5.0 (2.0--22.0)                             0.951
  FIGO stage *n* (%)                                                                                                                         0.002[b](#t2-fn3){ref-type="fn"}
  Stage 1                                                                  3 (13.6)                              27 (31.4)                                   
  Stage 2                                                                  4 (18.2)                              32 (37.2)                                   
  Stage 3                                                                  8 (36.4)                              22 (25.6)                                   
  Stage 4                                                                  7 (31.8)                               5 (5.8)                                    
  Treatment *n* (%)                                                                                                                                          
  Radical vulvectomy                                                      14 (63.6)                              55 (64.0)                                1.000
  Radical local excision                                                   8 (36.4)                              31 (36.0)                                   
  Adjuvant radiotherapy                                                   14 (63.6)                              29 (33.7)                   0.020[b](#t2-fn3){ref-type="fn"}
  Adjuvant chemotherapy                                                     (0.0)                                 1 (1.2)                                    
  HPV positive *n* (%)                                                      (0.0)                                18 (20.9)                   0.011[b](#t2-fn3){ref-type="fn"}
  Lymph node metastases *n* (%)                                           15 (68.2)                              26 (30.2)                   0.002[b](#t2-fn3){ref-type="fn"}
  Unilateral                                                               8 (36.4)                              21 (24.4)                   0.001[b](#t2-fn3){ref-type="fn"}
  Bilateral                                                                7 (31.8)                               5 (5.8)                                    
  Extracapsular growth                                                     8 (36.4)                               9 (10.5)                   0.006[b](#t2-fn3){ref-type="fn"}
  Tumour size (mm)[c](#t2-fn4){ref-type="fn"}                            38.7 (21.4)                            30.5 (22.2)                               0.610
  Infiltration depth (mm)[a](#t2-fn2){ref-type="fn"}                   8.0 (4.5--12.0)                        6.0 (3.0--11.0)                             0.242
  Vasoinvasion *n* (%)                                                     6 (27.3)                               9 (8.3)                                 0.077
  Lymfangioinvasion                                                        1 (4.6)                                2 (2.3)                                 0.499
  Perineural growth                                                        1 (4.6)                                3 (3.5)                                 1.000
  Positive resection margins                                               7 (31.8)                              14 (16.3)                                0.131
  Disease status *n* (%)                                                                                                                                     
  Complete remission                                                      11 (50.0)                              72 (83.7)                   0.003[b](#t2-fn3){ref-type="fn"}
  Local recurrence                                                         5 (22.7)                              17 (19.8)                                0.771
  Second primary tumour                                                    2 (9.1)                                8 (9.3)                                 1.000
  Regional recurrence                                                      2 (9.1)                                7 (8.1)                                 1.000
  Regional metastases                                                      1 (4.5)                                7 (8.1)                                 0.443
  Distant metastases                                                       7 (31.8)                              17 (19.8)                                   
  Died                                                                    18 (81.8)                              41 (47.7)                   0.007[b](#t2-fn3){ref-type="fn"}
  Disease-specific death                                                  11 (50.0)                              17 (19.8)                   0.002[b](#t2-fn3){ref-type="fn"}
  5-year overall survival % (s.d.)                                        27.3 (9.5)                             58.2 (5.6)                 0.00041[b](#t2-fn3){ref-type="fn"}
  5-year disease-specific survival % (s.d.)                              45.2 (11.4)                             79.7 (4.6)                 0.00057[b](#t2-fn3){ref-type="fn"}
  5-year disease-free survival % (s.d.)                                  25.0 (12.5)                             44.3 (6.6)                               0.149

Abbreviations: FIGO=International Federation of Gynecology and Obstetrics; HPV=human papillomavirus.

Median (interquartile range).

Significant difference (*P*\<0.05).

Mean (s.d.).

###### Multivariate analysis of prognostic variables

                               ***P*****-value**   **HR**    **95% CI for HR**
  ---------------------------- ------------------- -------- -------------------
  **Step 0**                                                
  Spindle cell morphology      0.001               3.503       1.632--7.517
  **Step 1**                                                
  Spindle cell morphology      0.011               2.706       1.262--5.805
  Age                          0.493               1.001       0.998--1.003
  HPV infection                0.970               0.000            NA
  **Step 2**                                                
  Spindle cell morphology      0.026               2.512       1.119--5.639
  Age                          0.850               1.000       0.997--1.002
  HPV infection                0.971               0.000            NA
  Tumour size                  0.205               1.016       0.991--1.042
  Infiltration depth           0.906               1.004       0.940--1.072
  Positive resection margins   0.335               1.734       0.566--5.306
  **Step 3**                                                
  Spindle cell morphology      0.003               4.135       1.613--10.601
  Age                          0.348               0.999       0.996--1.001
  HPV infection                0.964               0.000            NA
  Tumour size                  0.050               1.028       1.000--1.057
  Infiltration depth           0.562               0.984       0.930--1.040
  Positive resection margins   0.047               3.183       1.015--9.979
  Lymph node metastasis        0.509               1.364       0.543--3.427
  Metastasis                                                          
   No metastasis               0.000               Ref.               
   Locoregional metastasis     0.001               14.807      3.204--68.425
   Distant metastasis          0.000               39.734     11.341--139.214

Abbreviations: CI=confidence interval; HPV=human papillomavirus; HR=hazard ratio; NA=not applicable.

Variables added in step 1: age, HPV. Variables added in step 2: tumour size, infiltration depth, positive resection margins. Variables added in step 3: lymph node metastases, infiltration depth, metastases.
